In a randomized Phase II study, patients with advanced GC and gastroesophageal junction (GEJ) adenocarcinoma with immunohistochemical expression of FGFR2b or FGFR2 amplification via circulating tumor DNA (ctDNA) were treated with chemotherapy +/− bemarituzumab, a recombinant monoclonal antibody against FGFR2b.11 The overall survival (OS) favored bemarituzumab (19.2 months vs 13.5 months for placebo [HR 0.60, 95% CI 0.38-0.94]) in the post hoc analysis with an additional long-term follow-up of 12.5 months. Here, FGFR2 is linked to neoplasm.